Impact of HPV-Related Head and Neck Cancer in Clinical Trials: Opportunity to Translate Scientific Insight into Personalized Care

Christine H. Chung; David L. Schwartz

doi:10.1016/j.otc.2012.04.002

Impact of HPV-Related Head and Neck Cancer in Clinical Trials: Opportunity to Translate Scientific Insight into Personalized Care

Christine H. Chung, David L. Schwartz

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.

Original language	English (US)
Pages (from-to)	795-806
Number of pages	12
Journal	Otolaryngologic Clinics of North America
Volume	45
Issue number	4
DOIs	https://doi.org/10.1016/j.otc.2012.04.002
State	Published - Aug 1 2012

Keywords

Biomarkers
Chemotherapy
Clinical trials
Head and neck cancer
Human papillomavirus
Radiotherapy

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1016/j.otc.2012.04.002

Cite this

@article{c795e9b4cc6549df88df23c93e45ed0c,

title = "Impact of HPV-Related Head and Neck Cancer in Clinical Trials: Opportunity to Translate Scientific Insight into Personalized Care",

abstract = "Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.",

keywords = "Biomarkers, Chemotherapy, Clinical trials, Head and neck cancer, Human papillomavirus, Radiotherapy",

author = "Chung, {Christine H.} and Schwartz, {David L.}",

year = "2012",

month = aug,

day = "1",

doi = "10.1016/j.otc.2012.04.002",

language = "English (US)",

volume = "45",

pages = "795--806",

journal = "Otolaryngologic Clinics of North America",

issn = "0030-6665",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Impact of HPV-Related Head and Neck Cancer in Clinical Trials

T2 - Opportunity to Translate Scientific Insight into Personalized Care

AU - Chung, Christine H.

AU - Schwartz, David L.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.

AB - Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.

KW - Biomarkers

KW - Chemotherapy

KW - Clinical trials

KW - Head and neck cancer

KW - Human papillomavirus

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84863876312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863876312&partnerID=8YFLogxK

U2 - 10.1016/j.otc.2012.04.002

DO - 10.1016/j.otc.2012.04.002

M3 - Review article

C2 - 22793853

AN - SCOPUS:84863876312

SN - 0030-6665

VL - 45

SP - 795

EP - 806

JO - Otolaryngologic Clinics of North America

JF - Otolaryngologic Clinics of North America

IS - 4

ER -

Impact of HPV-Related Head and Neck Cancer in Clinical Trials: Opportunity to Translate Scientific Insight into Personalized Care

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this